Micropapillary bladder cancer A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience. The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated a...
Saved in:
Published in | Cancer Vol. 110; no. 1; pp. 62 - 67 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Wiley-Liss
01.07.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.
The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.
The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.
Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy. |
---|---|
AbstractList | Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.
The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.
The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.
Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy. Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.BACKGROUNDMicropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience.The authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.METHODSThe authors reviewed the records of 100 consecutive patients with micropapillary bladder cancer who were evaluated at The University of Texas M. D. Anderson Cancer Center.The mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.RESULTSThe mean age of the patients was 64.7 years, with a male:female ratio of 10:1. The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients. Kaplan-Meier estimates of 5-year and 10-year overall survival (OS) rates were 51% and 24%, respectively. Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease. Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups. For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years. For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.Micropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.CONCLUSIONSMicropapillary bladder cancer is associated with a poor prognosis. Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy. |
Author | Detry, Michelle A. Kamat, Ashish M. Grossman, H. Barton Siefker‐Radtke, Arlene O. Pisters, Louis L. Tamboli, Pheroze Robinson, Tracy L. Gee, Jason R. Dinney, Colin P. N. |
Author_xml | – sequence: 1 givenname: Ashish M. surname: Kamat fullname: Kamat, Ashish M. – sequence: 2 givenname: Colin P. N. surname: Dinney fullname: Dinney, Colin P. N. – sequence: 3 givenname: Jason R. surname: Gee fullname: Gee, Jason R. – sequence: 4 givenname: H. Barton surname: Grossman fullname: Grossman, H. Barton – sequence: 5 givenname: Arlene O. surname: Siefker‐Radtke fullname: Siefker‐Radtke, Arlene O. – sequence: 6 givenname: Pheroze surname: Tamboli fullname: Tamboli, Pheroze – sequence: 7 givenname: Michelle A. surname: Detry fullname: Detry, Michelle A. – sequence: 8 givenname: Tracy L. surname: Robinson fullname: Robinson, Tracy L. – sequence: 9 givenname: Louis L. surname: Pisters fullname: Pisters, Louis L. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18848913$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17542024$$D View this record in MEDLINE/PubMed |
BookMark | eNpt0EtLAzEUBeAgFfvQjXulG10IU29ek8yyFF9QcaPgLqR5QGQ6MybThf_e1FYK4ioEvuTec8Zo0LSNQ-gcwwwDkFvTmDgjRPDyCI0wVKIAzMgAjQBAFpzR9yEap_SRr4JweoKGWHBGgLARungOJrad7kJd6_g1XdXaWhenRjfGxVN07HWd3Nn-nKC3-7vXxWOxfHl4WsyXhSEU-mLFicEYU1mB9s54cAx7i7nIQ6QUtCTWWys8K4232lKpq8pZS7g3lpuS0gm63v3bxfZz41Kv1iEZl1dqXLtJSkDJypKKDC_3cLNaO6u6GNZ5bfUbKIOrPdDJ6NrHnCOkg5OSyQpvJ97sXE6fUnT-QEBtW1XbVtVPqxnDH2xCr_vQNn3Uof7vyTeJeni6 |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1097_COC_0b013e3182a53295 crossref_primary_10_1016_j_eursup_2009_06_009 crossref_primary_10_1111_j_1464_410X_2012_11751_x crossref_primary_10_1097_MOU_0000000000000356 crossref_primary_10_3389_fsurg_2021_754741 crossref_primary_10_1016_j_juro_2012_10_054 crossref_primary_10_1097_PAT_0b013e3283560172 crossref_primary_10_1038_modpathol_2009_26 crossref_primary_10_1016_j_urology_2010_11_043 crossref_primary_10_3390_biomedicines13010086 crossref_primary_10_1007_s00120_010_2484_4 crossref_primary_10_1111_bju_13689 crossref_primary_10_1097_MOU_0b013e3283495758 crossref_primary_10_3109_00313025_2010_522173 crossref_primary_10_3233_BLC_170156 crossref_primary_10_1016_j_clgc_2020_12_003 crossref_primary_10_1097_MOU_0b013e328356adff crossref_primary_10_1002_cncr_31952 crossref_primary_10_1016_j_mpdhp_2013_08_005 crossref_primary_10_1038_modpathol_2009_16 crossref_primary_10_1111_his_14161 crossref_primary_10_1007_s11255_022_03358_3 crossref_primary_10_1016_j_eururo_2012_08_009 crossref_primary_10_3390_curroncol30100638 crossref_primary_10_1016_j_urolonc_2014_06_012 crossref_primary_10_1097_PAS_0b013e3181962dcd crossref_primary_10_2214_AJR_08_1318 crossref_primary_10_1159_000375411 crossref_primary_10_22465_kjuo_2017_15_3_121 crossref_primary_10_4274_uob_galenos_2023_2023_8_1 crossref_primary_10_1111_j_1464_410X_2008_07968_x crossref_primary_10_1016_j_ypat_2010_11_020 crossref_primary_10_1097_PAS_0000000000002077 crossref_primary_10_1111_j_1442_2042_2010_02672_x crossref_primary_10_1016_j_juro_2013_07_061 crossref_primary_10_1097_MOU_0b013e328356ade6 crossref_primary_10_1111_j_1464_410X_2009_08694_x crossref_primary_10_4103_UCCI_UCCI_14_24 crossref_primary_10_1016_j_urolonc_2019_01_026 crossref_primary_10_1016_j_eururo_2016_02_056 crossref_primary_10_2217_fon_2016_0056 crossref_primary_10_32948_auo_2019_07_01 crossref_primary_10_3389_fsurg_2022_1037203 crossref_primary_10_5858_133_1_62 crossref_primary_10_1016_j_urology_2014_06_032 crossref_primary_10_1016_j_urolonc_2014_03_008 crossref_primary_10_1136_jclinpath_2013_201799 crossref_primary_10_5301_RU_2012_9369 crossref_primary_10_1007_s00428_017_2190_3 crossref_primary_10_1007_s11864_024_01187_3 crossref_primary_10_1016_j_juro_2009_02_116 crossref_primary_10_1016_j_urolonc_2012_04_020 crossref_primary_10_1007_s11255_022_03104_9 crossref_primary_10_1038_s41598_020_76904_7 crossref_primary_10_1080_2090598X_2021_1994230 crossref_primary_10_1111_j_1365_2559_2008_03167_x crossref_primary_10_1007_s00428_016_2001_2 crossref_primary_10_1016_j_eururo_2018_06_024 crossref_primary_10_2169_internalmedicine_7477_21 crossref_primary_10_23736_S2724_6051_23_05091_7 crossref_primary_10_4103_HUAJ_HUAJ_41_21 crossref_primary_10_1111_pin_12314 crossref_primary_10_1111_j_1464_410X_2009_09151_x crossref_primary_10_1016_j_eururo_2014_08_031 crossref_primary_10_1177_030089161009600231 crossref_primary_10_1007_s00428_016_1986_x crossref_primary_10_1016_j_juro_2014_09_092 crossref_primary_10_1007_s00345_014_1387_1 crossref_primary_10_1016_j_urolonc_2024_01_002 crossref_primary_10_1016_j_eururo_2016_12_002 crossref_primary_10_1016_j_humpath_2012_04_013 crossref_primary_10_1016_j_eururo_2012_10_008 crossref_primary_10_1097_PAS_0b013e3181a5387b crossref_primary_10_1155_2011_217153 crossref_primary_10_1097_PAP_0000000000000309 crossref_primary_10_1016_j_urolonc_2018_10_013 crossref_primary_10_1159_000514759 crossref_primary_10_1016_j_eururo_2016_02_028 crossref_primary_10_1016_j_urolonc_2024_09_005 crossref_primary_10_1097_PAP_0b013e3181d97851 crossref_primary_10_1016_j_clgc_2015_09_013 crossref_primary_10_1111_his_13958 crossref_primary_10_4103_1742_6413_107986 crossref_primary_10_1007_s11934_014_0450_1 crossref_primary_10_3892_mco_2024_2778 crossref_primary_10_1097_MOU_0b013e328363e415 crossref_primary_10_1007_s11523_014_0341_x crossref_primary_10_1016_j_clgc_2023_10_006 crossref_primary_10_1016_j_hoc_2014_10_009 crossref_primary_10_1002_dc_22866 crossref_primary_10_1016_j_euo_2023_07_012 crossref_primary_10_1016_j_humpath_2016_07_014 crossref_primary_10_1016_j_juro_2011_06_012 crossref_primary_10_3233_BLC_190257 crossref_primary_10_1016_j_euo_2019_09_003 crossref_primary_10_3233_BLC_160062 crossref_primary_10_1016_j_euf_2016_06_007 crossref_primary_10_3390_app10207102 crossref_primary_10_1038_nrurol_2011_144 crossref_primary_10_3233_BLC_160066 crossref_primary_10_1111_bju_13780 crossref_primary_10_1016_j_humpath_2009_04_002 crossref_primary_10_1016_j_euf_2020_08_010 crossref_primary_10_1016_j_hoc_2014_10_011 crossref_primary_10_1016_j_clgc_2015_04_008 crossref_primary_10_1080_14737140_2020_1784011 crossref_primary_10_1097_CCO_0b013e32835eb583 crossref_primary_10_1111_ijcp_12075 crossref_primary_10_1200_JCO_2014_57_6967 crossref_primary_10_1016_j_ucl_2013_01_012 crossref_primary_10_1111_cyt_12689 crossref_primary_10_5858_arpa_2017_0539_RA crossref_primary_10_1007_s13193_022_01692_7 crossref_primary_10_1016_j_anndiagpath_2022_151923 crossref_primary_10_1097_PAS_0b013e3181ec86b3 crossref_primary_10_1016_j_clgc_2019_11_005 crossref_primary_10_1016_j_clgc_2020_06_004 crossref_primary_10_1684_bdc_2010_1097 crossref_primary_10_3109_00313021003767314 crossref_primary_10_1097_PAP_0b013e318199f89e crossref_primary_10_1016_j_humpath_2009_07_015 crossref_primary_10_1002_dc_21555 crossref_primary_10_1016_j_path_2015_07_004 crossref_primary_10_1111_bju_12877 crossref_primary_10_4103_UCCI_UCCI_16_24 crossref_primary_10_21037_amj_2020_02_02 crossref_primary_10_1016_j_humpath_2009_11_018 crossref_primary_10_1016_j_urolonc_2022_02_004 crossref_primary_10_1016_j_clgc_2023_04_002 crossref_primary_10_1097_MOU_0000000000000089 crossref_primary_10_4132_KoreanJPathol_2013_47_4_365 crossref_primary_10_1016_j_anndiagpath_2019_02_013 crossref_primary_10_1097_MOU_0000000000000086 crossref_primary_10_1016_j_ebiom_2016_08_051 crossref_primary_10_1007_s00428_021_03264_6 crossref_primary_10_1007_s11912_022_01219_x crossref_primary_10_1016_j_euf_2021_04_005 crossref_primary_10_1016_j_path_2008_07_004 crossref_primary_10_1186_s12894_023_01183_z crossref_primary_10_1038_nrurol_2017_30 crossref_primary_10_1007_s12094_017_1658_6 crossref_primary_10_1016_j_urolonc_2012_04_009 crossref_primary_10_1016_j_prp_2009_07_016 crossref_primary_10_1016_j_clgc_2020_10_002 crossref_primary_10_1016_j_urolonc_2014_01_020 crossref_primary_10_1186_s13045_022_01291_7 crossref_primary_10_1038_modpathol_2011_69 crossref_primary_10_1093_jjco_hyy066 crossref_primary_10_1016_j_euo_2019_06_012 crossref_primary_10_1016_j_urology_2011_03_021 crossref_primary_10_3390_cancers14215440 crossref_primary_10_1007_s00428_017_2099_x crossref_primary_10_1038_modpathol_2014_158 crossref_primary_10_1016_j_urolonc_2017_10_013 crossref_primary_10_1097_PAP_0b013e31817d79b9 crossref_primary_10_1186_1471_2490_9_5 crossref_primary_10_5858_arpa_2018_0206_RA crossref_primary_10_1007_s11912_019_0772_8 crossref_primary_10_1002_dc_24981 crossref_primary_10_1016_j_humpath_2016_10_021 crossref_primary_10_5858_arpa_2011_0463_OA crossref_primary_10_1016_j_eururo_2018_11_052 crossref_primary_10_1590_S1677_5538_IBJU_2014_02_06 crossref_primary_10_1016_j_eururo_2012_09_063 crossref_primary_10_1186_1471_2407_13_71 crossref_primary_10_1097_PAS_0b013e3181a8ffbe crossref_primary_10_1016_j_urolonc_2014_10_001 crossref_primary_10_1200_EDBK_438640 crossref_primary_10_1016_j_semradonc_2022_10_008 crossref_primary_10_3233_BLC_170111 crossref_primary_10_1111_j_1464_410X_2007_07271_x crossref_primary_10_3892_mco_2018_1786 crossref_primary_10_1007_s00345_012_0976_0 crossref_primary_10_1016_j_euf_2021_07_015 crossref_primary_10_1158_1078_0432_CCR_13_1992 crossref_primary_10_32948_auo_2022_12_28 crossref_primary_10_12688_f1000research_14903_1 crossref_primary_10_4081_rt_2011_e22 crossref_primary_10_1111_tid_12072 crossref_primary_10_1016_j_juro_2014_02_2565 crossref_primary_10_1002_cncr_29826 crossref_primary_10_1111_j_1464_410X_2008_07962_x crossref_primary_10_1097_MOU_0b013e328356aecf crossref_primary_10_1002_dc_21011 crossref_primary_10_1016_j_humpath_2018_03_015 crossref_primary_10_1007_s11912_011_0161_4 crossref_primary_10_1016_j_urolonc_2008_10_022 crossref_primary_10_1097_MOU_0000000000001023 crossref_primary_10_4236_ss_2012_37068 crossref_primary_10_1016_j_ucl_2013_01_003 crossref_primary_10_1038_nrurol_2017_125 crossref_primary_10_1038_modpathol_2013_201 crossref_primary_10_1016_S0140_6736_16_30512_8 crossref_primary_10_1097_PAS_0000000000001453 crossref_primary_10_1016_j_euf_2019_09_003 crossref_primary_10_1093_ndtplus_sfp025 crossref_primary_10_32948_auo_2021_12_28 crossref_primary_10_1097_PAS_0000000000000241 |
Cites_doi | 10.1016/S0022-5347(05)00423-4 10.1200/JCO.2001.19.20.4005 10.1097/00000478-199412000-00005 10.1016/S0022-5347(05)68807-6 10.1002/cncr.21676 10.1002/cncr.10789 10.3322/canjclin.56.2.106 10.1111/j.1365-2559.2004.01895.x 10.1097/01.ju.0000132413.85866.fc |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS Copyright (c) 2007 American Cancer Society. |
Copyright_xml | – notice: 2007 INIST-CNRS – notice: Copyright (c) 2007 American Cancer Society. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1002/cncr.22756 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 67 |
ExternalDocumentID | 17542024 18848913 10_1002_cncr_22756 |
Genre | Journal Article |
GeographicLocations | United States North America Texas America |
GeographicLocations_xml | – name: Texas |
GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 29B 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAQOH AARRQ AAWTL AAXRX AAYCA AAYXX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGNAY AGYGG AHBTC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CITATION CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HF~ HGLYW HHY HHZ HZ~ H~9 IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RSU RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y VH1 W8V W99 WBKPD WH7 WHG WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XPP XV2 Y6R YQJ Z0Y ZGI ZXP ZZTAW ~IA ~WT AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW 24P AEUQT AFPWT CGR CUY CVF DIK ECM EIF NPM RWI VXZ WRC 7X8 |
ID | FETCH-LOGICAL-c230t-b52c1113890afecf0e41fd157420887362dfdd7f46cfdad38a99edd25fcd5c633 |
ISSN | 0008-543X |
IngestDate | Fri Jul 11 13:29:03 EDT 2025 Wed Feb 19 02:11:26 EST 2025 Mon Jul 21 09:14:25 EDT 2025 Thu Apr 24 22:59:17 EDT 2025 Tue Jul 01 01:22:06 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Human Urinary system disease Micropapillary carcinoma Urinary tract disease Transitional cell carcinoma Malignant tumor Bladder cancer Chemotherapy Cystectomy Cancerology Treatment University Surgery Bladder disease micropapillary transitional cell carcinoma Bibliographic review |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright (c) 2007 American Cancer Society. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c230t-b52c1113890afecf0e41fd157420887362dfdd7f46cfdad38a99edd25fcd5c633 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17542024 |
PQID | 70646637 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_70646637 pubmed_primary_17542024 pascalfrancis_primary_18848913 crossref_primary_10_1002_cncr_22756 crossref_citationtrail_10_1002_cncr_22756 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-07-01 |
PublicationDateYYYYMMDD | 2007-07-01 |
PublicationDate_xml | – month: 07 year: 2007 text: 2007-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2007 |
Publisher | Wiley-Liss |
Publisher_xml | – name: Wiley-Liss |
References | e_1_2_5_9_2 e_1_2_5_8_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_5_2 e_1_2_5_4_2 e_1_2_5_3_2 e_1_2_5_2_2 |
References_xml | – ident: e_1_2_5_5_2 doi: 10.1016/S0022-5347(05)00423-4 – ident: e_1_2_5_6_2 doi: 10.1200/JCO.2001.19.20.4005 – ident: e_1_2_5_3_2 doi: 10.1097/00000478-199412000-00005 – ident: e_1_2_5_4_2 doi: 10.1016/S0022-5347(05)68807-6 – ident: e_1_2_5_10_2 doi: 10.1002/cncr.21676 – ident: e_1_2_5_8_2 doi: 10.1002/cncr.10789 – ident: e_1_2_5_2_2 doi: 10.3322/canjclin.56.2.106 – ident: e_1_2_5_7_2 doi: 10.1111/j.1365-2559.2004.01895.x – ident: e_1_2_5_9_2 doi: 10.1097/01.ju.0000132413.85866.fc |
SSID | ssj0007253 |
Score | 2.3757727 |
Snippet | Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 62 |
SubjectTerms | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Papillary - drug therapy Carcinoma, Papillary - pathology Carcinoma, Papillary - surgery Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - surgery Combined Modality Therapy Cystectomy - methods Female Hospitals, University Humans Male Medical sciences Middle Aged Neoadjuvant Therapy - methods Neoplasm Staging Nephrology. Urinary tract diseases Retrospective Studies Survival Analysis Texas Tumors Tumors of the urinary system Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland |
Subtitle | A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients |
Title | Micropapillary bladder cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17542024 https://www.proquest.com/docview/70646637 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA66gggi3h0va0BfpExtO-2045vM7jrIdhXpwL6VNBcUls7QdkD9Bf5sz0nSpoMrXl46JSSlnfPl5Evy5RxCXqpqLlmYVNDF-WIaSwVdKqnwLqkYW8y40mk687P5ah2_P09GG-36dElX-fz7pedK_seqUAZ2xVOy_2DZ4aFQAPdgX7iCheH6VzbOUU23ZVvMHNR886oLdCMNCrm4bMwxZnc0xTLMkQyjkF9Z6-W-d-SjsFFzb2-pG-tVX_iRQyRks2IbBgEK1VvJd1pzZMOytmOOa54weHIGnFh7oPYzRk9ya-NfeqXZEhMHeR_drtA7qw5i-EIjiRAM6HbBdoUbJZ2FVL9okQ4CV-eIs2kS61TAzhFbgesYccatGof9i7c30WN5zRs_wjD2bkzr9_HPPpQn69PTsjg-L66SaxHMJfS8-5OLMZZGNlSpfaMhhm302j15j7Xc3LIWOpAymU9-PzXRFKW4TW7ZuQV9a4Byh1yR9V1yPbfqiXvkxz5eqMULNXh5Qxk1aKEbRQEt1KEFSzRaaO7TI5_2aKHG1tSghTq0UEQLhc-jI7TQHi33yfrkuFiupjYTx5TDFLWbVknEYVAEchswJbkKZBwqESYpijOyFEiQUEKkKp5zJZiYZWyxkEJEieIi4fPZ7AE5qDe1fESokKGKRRKygEcxcNmKCQmUtIKJAldxFE7Iq_6fLrkNU4_ZUi5KE2A7KtEqpbbKhLwY6m5NcJZLax3uGcxVzbIYd-kn5HlvwRKcK-6YsVpudm2ZAmEHSp5OyENjWNcWM0cDv338x7ZPyA3XA56Sg67ZyWdAZLvqUAPxJ8Zmo5I |
linkProvider | Wiley-Blackwell |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Micropapillary+bladder+cancer%3A+a+review+of+the+University+of+Texas+M.+D.+Anderson+Cancer+Center+experience+with+100+consecutive+patients&rft.jtitle=Cancer&rft.au=Kamat%2C+Ashish+M&rft.au=Dinney%2C+Colin+P+N&rft.au=Gee%2C+Jason+R&rft.au=Grossman%2C+H+Barton&rft.date=2007-07-01&rft.issn=0008-543X&rft.volume=110&rft.issue=1&rft.spage=62&rft_id=info:doi/10.1002%2Fcncr.22756&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |